Edgewise Therapeutics, Inc. EWTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s accrued expenses?
- Edgewise Therapeutics, Inc. (EWTX) reported accrued expenses of $5.68M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Edgewise Therapeutics, Inc.'s accrued expenses increased by 42.9% year-over-year, from $3.97M to $5.68M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s accrued expenses has grown at a 60.3% compound annual growth rate (CAGR), from $1.18M to $12.43M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.